News articles about Protagonist Therapeutics (NASDAQ:PTGX) have been trending somewhat positive on Saturday, Accern reports. The research group rates the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Protagonist Therapeutics earned a news impact score of 0.06 on Accern’s scale. Accern also gave headlines about the company an impact score of 43.2115870413161 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Shares of Protagonist Therapeutics (PTGX) opened at $17.57 on Friday. The company has a market capitalization of $358.94 and a P/E ratio of -6.32. Protagonist Therapeutics has a 52 week low of $8.00 and a 52 week high of $23.75.
Several analysts have recently commented on PTGX shares. Zacks Investment Research raised Protagonist Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 price objective for the company in a research note on Saturday, November 11th. BidaskClub raised Protagonist Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, December 29th. Stifel Nicolaus started coverage on Protagonist Therapeutics in a research note on Monday, January 29th. They issued a “buy” rating and a $32.00 price objective for the company. Finally, BMO Capital Markets increased their price objective on Protagonist Therapeutics from $40.00 to $43.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 7th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $32.50.
In other news, insider Dinesh V. Ph D. Patel sold 1,790 shares of the stock in a transaction that occurred on Wednesday, December 20th. The stock was sold at an average price of $19.55, for a total value of $34,994.50. Following the completion of the sale, the insider now directly owns 192,227 shares of the company’s stock, valued at $3,758,037.85. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Thomas P. O’neil sold 8,000 shares of the stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $20.00, for a total value of $160,000.00. Following the completion of the sale, the chief financial officer now directly owns 4,000 shares of the company’s stock, valued at $80,000. The disclosure for this sale can be found here. Over the last three months, insiders sold 15,944 shares of company stock valued at $319,839. Company insiders own 15.50% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This article was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://www.dispatchtribunal.com/2018/02/17/protagonist-therapeutics-ptgx-receives-daily-media-sentiment-score-of-0-06.html.
Protagonist Therapeutics Company Profile
Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.